PharmacoEconomics

Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events: Economic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective
pp. 955-973(19)
Authors: Peter K. Schädlich; Josef G. Brecht; Badrudin Rangoonwala; Eduard Huppertz

Does Seropositivity for Helicobacter pylori Antibodies Increase Outpatient Costs for Gastric and Duodenal Ulcer or Inflammation?
pp. 975-983(9)
Authors: Akira Babazono; Motonobu Miyazaki; Hiroshi Une; Eiji Yamamoto; Toshihide Tsuda; Yoshio Mino; Alan L. Hillman

Economic Impact of Migraine and Other Episodic Headaches in France: Data from the GRIM2000 Study
pp. 985-999(15)
Authors: André Pradalier; Jean-Paul Auray; Abdelkader El Hasnaoui; Kazem Alzahouri; Jean-François Dartigues; Gérard Duru; Patrick Henry; Michel Lantéri-Minet; Christian Lucas; Guy Chazot; Anne-François Gaudin

Comparisons of Hypertension-Related Costs from Multinational Clinical Studies
pp. 1001-1014(14)
Authors: C. Daniel Mullins; Mirko Sikirica; Viran Seneviratne; Jeonghoon Ahn; Kasem S. Akhras

Cost Effectiveness of ACE Inhibitor Treatment for Patients with Type 1 Diabetes Mellitus
pp. 1015-1027(13)
Authors: Frederick B. Dong; Stephen W. Sorensen; Diane L. Manninen; Theodore J. Thompson; Venkat Narayan; Carlyn E. Orians; Edward W. Gregg; Richard C. Eastman; Erik J. Dasbach; William H. Herman; Jeffrey M. Newman; Andrew S. Narva; David J. Ballard; Michael M. Engelgau